NCT03879382View on ClinicalTrials.gov

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES

PHASE1UnknownINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 27, 2019

Primary Completion Date

August 30, 2020

Study Completion Date

May 30, 2022

Conditions
POMES SyndromeRelapsed and Refractory POMES Syndrome
Interventions
BIOLOGICAL

anti-CD19/BCMA CAR-T cells

Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-BCMA CARs

DRUG

Fludarabine

30mg/m2/d

DRUG

Cyclophosphamide

300mg/m2/d

Trial Locations (1)

200003

Shanghai Changzheng Hospital, Shanghai

Sponsors
All Listed Sponsors
collaborator

Shanghai Changzheng Hospital

OTHER

lead

Hrain Biotechnology Co., Ltd.

INDUSTRY